Archives of Pharmaceutical Sciences and Research E-ISSN0975-2633 | PRINTISSN0975-5284
Vol 15 Issue 1 001–017 June 2025 Review Article

# ADVANCE IN NASAL MUCOADHESIVE MICROSPHERES FOR TREATING ALZHEIMER'S DISEASE: A COMPREHENSIVE REVIEW

**Arbind Mahato*, S. Rajarajan, Beny Baby and K Ramesh**

Department of Pharmaceutics, Karnataka College of Pharmacy, Bangalore.

**ABSTRACT**

Progressions in nasal mucoadhesive microspheres speak to a promising technique for the treatment of Alzheimer's disease, a neurological disorder affecting roughly 3% of the elderly population worldwide. Current therapeutic alternatives, primarily cholinesterase inhibitors and NMDA receptor antagonists, mainly provide symptomatic relief and fail in addressing the underlying neurobiological components of the disease, such as amyloid-β aggregation and oxidative stress. Nasal drug delivery systems offer a significant advantage by bypassing the blood-brain barrier, enhancing drug delivery, and enabling targeted delivery to the central nervous system. Mucoadhesive microspheres enhance drug retention within the nasal cavity, allow controlled drug release, and improve treatment compliance, particularly among elderly and pediatric populations. This comprehensive audit highlights the potential of these inventive medicate conveyance frameworks to revolutionize advertising administration by giving non-invasive, compelling, and targeted therapeutic alternatives.

**Keywords:** Alzheimer's disease, Nasal drug delivery, Mucoadhesive microspheres, Blood-brain barrier, Neurological disorders

## 1. INTRODUCTION

Neurological degeneration is called Alzheimer's disease as an exasperating condition that effects of around 3% of all elderly individuals around the world. Specialists nowadays recognize Alzheimer's illness by shaping amyloid-β (Aβ) sheets on the dividers of gray matter and dividers of supply routes driving to amyloid vascular malady and nerve lymph hubs. The phantom is creating as a degenerative neuropathy, slowly driving to brain brokenness that moderates physical wellbeing and breaks down mental capacities. The therapeutic community centres on successful sedate administration strategies for phantoms, since it speaks to 70% of cases of memory misfortune over Australia whereas appearing the victory of cholinesterase inhibitors, as affirmed by the FDA and NMDA receptor blockers to treat its progression within the disease. [1,2,3,4]

### 1.1. Limitation of current treatment

The drugs cholinesterase inhibitors, at the side of NMDA receptor antagonists, as it were giving brief and little impacts on patients, whereas they lack the capacity to treat different factors that cause advertisement, including amyloid-oxygen accumulation and oxidative stress. Most of the treatments have a limit of the pass-through blood brain and is suitable for the dynamic stages of the disease and does not provide treatment for behaviour indications. [5]

### 1.2. Potential of nasal drug delivery

The intracranial method facilitates the increase in the use of the drug for protein for treatment and RNA drugs by ignoring the brain blood barrier, but protecting the patient from the unwanted system effects and directing the drug to the amyloid sheets as well as tangled with neuritis positions. The method of managing nasal drugs maintains excellent compatibility with future treatments related to insulin and defecation, as well as anti -inflammatory drugs, allowing patients to use them regularly and enhance treatment. [6]

### 1.3. Mucoadhesive microspheres for CNS targeting

Mucoadhesive microspheres speak to a methodology to improve brain uptake and residence time of drugs through nasal administration routes. The microspheres stick to nasal surfaces where they extend medicinal retention while enabling quantitative brain absorption through natural brain pathways that avoid passing through the blood-brain barrier (BBB). The drug's amplified brain maintenance through controlled discharge highlights of these microspheres decreases both treatment timing and upgrades understanding of medicine adherence. [7,8]

## 2. OVERVIEW OF NASAL DRUG DELIVERY




**Figure 1 :- Anatomy and physiology Nasal cavity**

### 2.1 Anatomy and Physiology of nasal cavity

The nasal depression stands as a fundamental structure within the upper respiratory tract, which carries out imperative capacities related to breathing, including filtration and humidification, and scent detection. Air filtration at the side temperature balance and humidification happens through the nasal depth, where three essential hard projections named turbinate (superior, central, and predominant) improve the filtration zone. Specialized tactile epithelium utilized for Odor discovery exists inside the nasal cavity at its roof. The nasal depression has pseudostratified ciliated columnar epithelium lining that serves to trap and remove discuss particles through the development of little hairs for the security of the airway pathway. The complex network shows the vital position of the nasal cavity for both respiratory system protection and pharmaceutical substance delivery. [9,10]




**Figure 2 :- Pathway of drug passage nose to brain**

Nasal Collector employees provide brain solutions using olfactory and trigeminal pathways that have a wide blood supply and proximity, avoid blood-brain boundaries and benefit neurological patients with Alzheimer's or Parkinson's disease. The depth of the nose allows the calm area to enter the body through transcellular assimilation and paraantinophyte anabolic assimilation than most retention pathways. The nasal mucosa, with a lean epithelial layer and adequate blood supply, promotes rapid drug assimilation directly into the bloodstream. Medical particles that use transcellular retention have lipophilic properties or vans, allowing them to pass through the inner nasal cells. A method of development sedated through near associations between epithelial cells is accomplished by preserving parazeruns, but urgent changes are used to advance this storage. Through its association with coordinates with the central concern of concern, the olfactory region allows sedatives to reach the CNS without exceeding the limits of the blood-brain. [11,12,13]

## 2.2 Challenges of Nasal Drug Delivery

Nasal drug delivery operates as an encouraging drug administration option compared to oral and injectable paths while presenting multiple logistical problems. The main constraint to drug absorption through the nasal mucosa arises due to the barrier function which hinders the penetration of large molecules along with hydrophilic drugs thus decreasing bioavailability. The rapid removal of substances from nasal cavities through mucociliary clearance stretches the time during which drugs stay in the nose. Consistent use of drugs through the nose results in mucosal discomfort which leads to dry mucosal tissue and physical damage thus affecting patient drug adherence. [14,15]

The formulation stability of nasal defect systems such as spray powders and emulsions is subject to instability as PH-PH changes and oxidation and contaminants reduce the drug. The similarity of dosage between patients remains inconsistent because patients have different nasal structures and they use spray differently and suffer from nasal swelling. High bioavailability remains challenging because the drug faces enzymatic breakdown and speedy clearance even though it avoids initial metabolism.[16]

## 2.3 Mechanism of Drug Absorption Through Nasal Route

Access to medication is blocked during nasal reinforcement as pathology (such as rhinitis or sinusitis) absorbs mucus. Current technology for nasal medication devices does not achieve the largest drug placement, so scientists need to create improved drug formulations and removal methods. New advances in drug carriers, bioadiv delivery systems and latest distribution technologies enable the feasibility and efficiency of infant pharmacies. [17,18]

The lipoidal barriers tightly restrict access of therapeutic drugs, along with foreign substances, into the CNS through their strict control mechanisms. Drug penetration through the brain barriers remains restricted because nearly 98% of drugs fail to cross these protective barriers, thus decreasing treatment prospects for neurological disorders like Parkinson`s disease (PD) alongside Alzheimer`s disease (AD). [19,20]

Although smaller than the BBB, this barrier protects CSF through limited drug passage because of its reduced surface area. The development of various improvement methods for nasal medication submission will continue as researchers treat reduced drug solubility, enzymatic degradation and rapid clearance. Nasal drug delivery was improved by three different drug delivery systems, including nanoparticles with liposomes and microemulsions, and enzyme inhibitors to prevent degradation of connections. Scientists have introduced new technology in delivery systems for nasal delivery to improve dose accuracy, reduce symptoms at the same time, and achieve better results for intranasal drug collection. [21]

## 2.4 Advantages of Nasal Drug Delivery

- Drug absorption through the nasal mucosa produces fast bloodstream access, which results in rapid drug effectiveness.
- Non-invasive – It provides a comfortable, needle-free alternative to injections.

- Consequences for first-pass metabolism are bypassed through this delivery system, which leads to improved drug bioavailability.
- The delivery method achieves optimal effects when localizing treatments for nasal and sinus conditions.
- Enhanced patient compliance – Easy self-administration benefits children and elderly patients.
- Versatility – It is suitable for small molecules, peptides, and vaccines.
- The drug-specific impact occurs only at targeted tissues, reducing harm spread across the body. [22,23]

## 3. MUCOADHESIVE MICROSPHERES

### 3.1. Define Mucoadhesive Microsphere

Mucoadhesive microsphere is a group of controlled drug management systems designed to follow the surfaces of the body's mucus, such as the digestive tract, nasal cavity, oral cavity, vagina or rectum. These microspheres are usually small spherical particles, usually including biodegradable polymers and mucus, which allows prolonged absorption and increases the bioavailability of the drug.[24]




**Figure 3 :- Structure of Microsphere**

Biologically resistant particles known as microspheres include mucus adhäsive polymers, carbopol, and alginates and hydroxypropylmethylcellulose (HPMC) and polyacrylic acids constructed from chitosan. The size range of microspheres is 1-1000 and allows efficient contact with the mucus membrane fabric, and acts as a controlled drug discharge for specific targets.[25]

### 3.2 Mechanism of Mucoadhesion

A polymeric microsphere establishes mucoadhesion by creating physicochemical, as well as biological interactions, which connect to the mucosal layer. The mucoadhesive process has two fundamental stages that follow one another.




**Figure 4: Two stage of mucoadhesion Process**

### Contact Stage (Wetting and Adsorption)

When the microscope is in contact with the mucus surface, it starts to expand through its border. Water -loving polymers have, strong affinity for water, absorb moisture, and grow in size. When they swell, they improve the ability to follow mucus, facilitating stronger cohesion to the surface of the mucus.[26]

### Consolidation Stage (Mechanical and Chemical Interactions)

The grip quality is improved by the thickness of many interfaces. Useful grapes in polymers maintain the charge that allows electrostatic intelligent to bind well to mucin. Furthermore, hydrogen bonds are formed between the extension groups of hydroxyls, carboxyl, or polymeric mucin glycoproteins upon attachment of bonds. Frail supplementary strength is called the strength of Van of the World and gives additional strength to the quality of the cement. Additionally, the polymeric diffuses into the physical fluid layer, creating complex web-like structures that advance and drug residence times at the application location. [27]

### 3.3 Factors Affecting Mucoadhesion [28,29]

- Multiple factors dictate how mucoadhesive microspheres adhere to bodily tissues during their operational period:
- The three key characteristics influencing polymers in mucoadhesion include molecular weight, along with charge density and hydrophilicity.
- Faster mucous turnover decreases how long medical assets stick to mucous membranes.
- Swelling capabilities and bonding interaction of polymers are subject to change based on pH levels and ionic strength, alongside hydration levels.
- Physiological factors: The presence of enzymes and mechanical movements, such as peristalsis, in the gastrointestinal tract.

### 3.4 Advantages of Mucoadhesive Microspheres

The drug delivery method using mucoadhesive microspheres provides multiple beneficial properties which demonstrates their potential as an effective therapeutic strategy.[30]

The bioavailability of drugs improves when microspheres stay on mucosal surfaces because drug retention extends while delivery remains controlled which results in better absorption compared to conventional oral formulations that quickly lose potency.[31]

The localized absorption capabilities of mucoadhesive microspheres reduce drug degradation in the first-pass metabolism process in the liver since they minimize drug breakdown to a major extent before reaching systemic circulation. These microspheres demonstrate promising aptitude for brain delivery because they enhance the ability of BBB penetration for drugs like quetiapine. [32]

### 3.5 Challenges in Mucoadhesive Microsphere Development

The selection of the right polymer represents a fundamental problem, as the selected material must achieve an ideal match between mucus layer capacity and drug exemption properties to provide effective mucosal binding and drug collection. [33] The extended time the microspheres spend bound to mucosal surfaces presents a challenge because it may generate tissue inflammation which demands precise formulation methods to deliver drugs safely. The effective utilization of mucoadhesive microspheres in drug delivery depends on solving these current challenges by improving their formulation methods using advanced polymer engineering approaches. [34]

### 3.6 Commonly Used Materials for Mucoadhesive Microspheres

Polymers play a central role in the design of mucoadhesive microspheres, controlling measures, surface charge, biodegradation, rate of calm conveyance, and cement potential. Chitosan, with a chitin source, updates connection due to the availability of decidedly charged amino units, though alginate, derived from brown alga, outlines gel-forming potential for sustained release. [37]

Common and engineered polymers are regularly utilized together in an endeavour to tailor Mucoadhesion as well as medicate delivery energy. Mucoadhesive microspheres may epitomize all sorts of drugs, counting peptides,

proteins, immunizations, and little atoms, with the sort of polymer controlling the cure discharge plan. With the use of appropriate polymers and crosslinkers, mucoadhesive microspheres may be defined for indeed superior medicate conveyance, attachment, and medicate discharge control. [38]

**Table 1: Polymer-based drug delivery systems of anti-Alzheimer drugs:**

| Drug | System | Components | Method |
|---|---|---|---|
| **Memantine** | PLGA NPs | PLGA | Probe sonication method |
| **Donepezil** | Chitosan NPs | Chitosan, sodium TPP | Ionic gelation technique |
| **Galantamine** | Chitosan-alginate NPs | Chitosan, STPP, alginic acid | Gelation method |
| **Rivastigmine** | Eudragit-coated chitosan NPs | Eudragit EPO, chitosan, span 80 and glutaraldehyde | Emulsion cross-linking |
| **Combination therapy (MEM+Donepezil)** | ApoE targeted SLNs | Apolipoprotein-E Polyethylene glycol, avidin | Homogenization sonication method |

## 3.7 Mechanism of Adhesion to Nasal Mucosa

Distinctive microorganisms along with allergens and sedative conveyance frameworks have to adhere to the nasal mucosa for effective interaction. The official handle contains four primary official components which incorporate electrostatic fascination along with hydrophobic powers in addition to biofilm improvement and unmistakable receptor-ligand authoritative intelligent.

### Electrostatic and Hydrophobic Interactions

Negative charges on mucosal surfaces make a cement layer through which attachment happens. Following capacity increments among microbes and particles if they both display complementary charge intuitive or have hydrophobic properties. [39]

### Mucin-Binding Proteins and Ligand-Receptor Interactions

Most pathogens and nanoparticles engage with mucin proteins and particular receptors (such as ICAM-1 for rhinoviruses) to establish binding interactions. Bacterial attachment sites for Streptococcus pneumoniae occur through glycoproteins present in mucus layers. [40]

### Biofilm Formation

The nasal mucosa surface becomes resistant to mucociliary clearance mechanisms when Staphylococcus aureus bacteria form biofilms on this surface. [41]

### Mucociliary Clearance Resistance

The adhesion mechanisms work by either attaching to epithelial cells or by making mucus viscous to evade mucociliary clearance. The use of mucoadhesive polymers including chitosan represents one form of drug delivery systems which enhance drug retention through the same protective mechanisms. [42]

## 3.8 Importance of sustained drug release

Maintainable strategies for medicate item discharge are fundamental to make strides the adequacy of the medicate and to progress the patient's readiness to take after treatment plans. Supported sedate discharge stops certain medicate levels within the blood. This makes a difference patients maintain a strategic distance from the hurtful side impacts of ordinary medicate organization and unsteady medicate concentrations.[43] Strategies to Control Medicate Discharge give medicate treatment agreeing to a reliable portions design to maximize treatment adequacy. Maintained sedate conveyance permits controlled substance discharge and successfully decreases the event of unfavorable impacts by decreasing concentration speakers that decreases the probability of overdose of solutions that smooth out

concentration speakers.[44] Therapeutic definitions are extended and diminish mucosal harm as they keep up a moderate discharge of the dynamic fixing over time to dodge tissue harm. Diligent conveyance of restorative items remains basically imperative for managing with diligent illness by keeping up a consistent level of sedate dissemination in patients with asthma, torment and tainted patients. [45]

## 4. PATHOLOGICAL OF ALZHEIMER'S DISEASE (A.D)

The essential source of Alzheimer`s disease (Advertisement) develops from the broken, collapsing, and conglomeration of actually soluble proteins that contain amyloid β and trigger the disintegration of brain cells. Two essential highlights of this illness are obvious as Aβ plaques between cells and NFTs (neurofibrillary tangles) made of hyperphosphorylated tau protein interior cells. Tau tangles develop because of Aβ aggregation, beginning within the locus coeruleus and trans entorhinal/entorhinal ranges, whereas moving to the hippocampus and neocortex afterward within the disease prepare. [46,47]




**Figure 5:- Pathology of A.D**

Multiple factors contribute to Alzheimer`s disease pathologies by Aβ plaque accumulation and NFT development, and through changes at synapses, neuron death, and the maintenance of brain tissue inflammation. Neurons experience damage because Aβ both disrupts synapses and produces inflammation and excessive oxidation in brain tissue. The aggregates termed NFTs comprise tau protein that experiences excessive phosphorylation while serving as the primary microtubule-associated protein inside cells. This problem disrupts transport processes inside neurons, producing cellular dysfunction, which creates conditions necessary for neuron mortality. [50]

Researchers believe that the accumulation of Aβ matter represents the main factor triggering AD-related pathology, while also causing tau hyperphosphorylation, synaptic breakdown, and neuron destruction at the molecular level. Oxidative stress, which develops from both Aβ accumulation and tau pathology, disrupts the energy production system and mitochondrial function. [51]

The risk of developing age-related dementia increases when cardiovascular diseases (hypertension, diabetes, and hypercholesterolemia) lead to brain vascular dysfunction due to environmental influences. Brain resilience increases, along with symptom delay, through cognitive reserve, which develops through education and intellectual engagement, and bilingualism. [52,53]

## 5. DRUG USED IN ALZHEIMER'S THERAPY

The treatment drugs for Alzheimer`s disease (Advertisement) exist in two essential classifications, specifically symptomatic treatments and disease-modifying treatments (DMTs). The main work of symptomatic medicines is to control cognitive and behavioral signs of Alzheimer's illness, whereas disease progression proceeds normally. [54,55]

The purpose of disease-modifying medicines is to assist patients with Advertisement through particular treatments planned to moderate the movement of amyloid plaques and tau tangles, and other disease forms. The restorative taken a toll of these drugs are tall, and they show the chance of creating amyloid-related imaging variations from the norm (ARIA). The helpful choices for Advancement treatment additionally solidify anti-inflammatory compounds, as well as directors that target blood vessels and ensure neural structures, and genetic treatment approaches. Patients with Alzheimer's infection need to get comprehensive care through both non-drug drugs, such as treatment sessions, nearby way of life adjustment programs and caregiver reinforce systems. [56,57]

**Table 2: Both classes of Drugs, NMDA receptor and AChE inhibitors are**

| Drug | Marketed brand name | Mechanism of action | Available formulation | Side effect |
|---|---|---|---|---|
| **Memantine** | Axura, Namenda, | NMDA receptor antagonist | Extended-release capsule | Dissiness, headache, confusion, diarrhea and constipation |
| **Donepezil** | Aricept, Alzepil, Dopezil | Ache inhibitor | Transdermal patch | Gastrointestinal side effect |
| **Galantamine** | Exelon, Prometax | Ache inhibitor | Transdermal patch | Gastrointestinal side effect |
| **Rivastigmine** | Nivalin, Reminyl | Ache inhibitor | Film coated tablet | Gastrointestinal side effect |
| **THA** | | Ache inhibitor | | High hepatotoxicity |

## 6. ADVANCE IN NASAL MUCOADHESIVE MICROSPHERES FOR A.D

Cutting-edge movements in treatment points of interest combined with advanced advancement have enabled predominant courses of action to handle the troublesome complications of Alzheimer's disease. Moves in sedate movement systems, which consolidate nanoparticles nearby nanogels and hydrogels, update the blood-brain boundary penetrability and solidness, though upgrading the bioavailability of accommodating drugs. Nanoparticles that carry functionalized components with ligands or antibodies work by centering on masters to reach amyloid-beta plaques and tau tangles interior the brain, and responsive points of interest trigger sedate releases interior hypochondriac regions with acidic or enzyme-rich conditions. Investigators are making monoclonal antibodies along with RNA-based medications to diminish central points of Alzheimer's pathology, starting from amyloid aggregation and concluding at tau hyperphosphorylation. Examiners are making monoclonal antibodies in conjunction with RNA-based medicines to target central points of Alzheimer's pathology, starting from amyloid aggregation and concluding at tau hyperphosphorylation. The healthcare industry is getting centered ultrasound contraptions, exosome movement systems, and receptor-mediated transport methodologies, to advance BBB penetration and actualize theranostic systems that mix demonstrative testing with supportive calm following highlights. Synergistic definitions deliver a technique for passing on diverse drugs at once to combat at the same time the shapes of neuroinflammation, nearby oxidative stress, and neuronal degeneration. The enhancement of specific and personalized medicines gets additional vitality from afterward imaginative rebellious, including AI-assisted medicate advancement systems and quality changing computer programs, at the side 3D bioprinters. These innovative approaches to treating Alzheimer's disease proceed to advance, in spite of challenges in security measures and flexibility, and authoritative obstructions, since they hold cutting-edge potential results for

prevalent medicines that are neighborly to patients. [58,59]

## 7. CASE STUDIES AND EXPERIMENTAL FINDINGS RELATED TO ALZHEIMER'S DISEASE (AD)

### Case Studies in Alzheimer's Disease

History acknowledges Henry Molaison (HM) as one of the most influential subjects from the memory research era because he underwent epilepsy surgery in 1953. Doctors removed sections from the medial temporal lobe, including the hippocampus, during the surgical operation. The surgical procedure led HM to develop extensive memory problems that specifically impaired his long-term memory creation (anterograde amnesia), yet he maintained unaltered access to past memory retrieval. yet he maintained unaltered access to past memory retrieval. Scientists established the critical importance of the hippocampus through evidence gathered from this medical case. Research involving HM's clinical case has advanced scientists' comprehension of Alzheimer's disease's effects on brain memory facilities, thus leading to novel therapeutic approaches for hippocampal and associated brain structures. [60]

An elderly understanding, 70 a long time confronted a determination of Mellow Cognitive Impedance (MCI), which restorative inquire about sees as a forerunner to Alzheimer's illness. The lady displayed with memory challenges that influenced her capacity to keep in mind later events, however did not satisfy the total necessities of Alzheimer's infection. A total Alzheimer’s infection conclusion was decided by means of neuropsychological screenings and brain imaging strategies taking after different a long time of perception, which affirmed MCI leads to Alzheimer's advancement. The case ponders affirmed that MCI acts as the primary stage of Alzheimer's illness whereas illustrating the require for opportune determination taken after by fitting mediation measures. Patients inclined to Alzheimer's malady may benefit from way of life alterations, beside cognitive treatment, which might moderate the improvement of their illness and give superior results. [61]

### Experimental Findings in Alzheimer’s Disease

The monoclonal counter-effective drug adcanumab (adcanumab) speaks in one of the latest drugs against amyloid plaque, which serves as a neurophysiological sign of Alzheimer's disease. Researchers have observed clinical studies on how adcanumab effectively reduces amyloid plaque in the brain, indicating that it may slow cognitive disruption of Alzheimer's disease in early-stage patients. In fact, it includes perception effects after the FDA approved the set best for its mixed test results in 2021. We believe that the accumulation of tau proteins builds the important role of substances in the pathology of Alzheimer's disease. This test shows that the tau transition arrangement causes a stronger cognitive decline compared to the amyloid plaques of Alzheimer's disease. Therapeutic communities conduct progressive clinical studies with small particles to treat monoclonal antibodies and the formation of exodus-related tangles. Advances in disease modifiers rely heavily on understanding dew pathology. [62,63]

Analysts have considered the advancement of BACE1 chemical inhibitors since it can dispose of amyloid-new generation. BACE1, Verubecetat and Lanabecestat inhibitors have demonstrated the initial success of reducing CTA amyloid sheets, but tests must be stopped due to incomplete risk of treatment and security services. The think about of quality treatment presents hereditary hazard components at the same time by centering on Alen Alen Apoe4, speaking to a major hereditary chance calculate for Alzheimer's illness. Initial research using priority systems in animal models has shown encouraging results related to the reduction of the biological brand of the disease and cognitive disorders, providing promising measures for patients at risk of Alzheimer's disease. [64] Patients advantage from more strategies that don't utilize virtual reality innovation to create mindfulness preparing. Alzheimer's patients use virtual reality systems in memory and memory navigation to display better memory performance, as well as increase cognitive flexibility, participation, and reduce anxiety symptoms. Research shows that virtual reality is a valuable tool to improve mental activities as well as the quality of life and terminate current treatments. Distinctive medications have made critical advance within the think about of Alzheimer's malady, but researchers confront

impediments to create successful medicines for all patients. [65]

## 8. METHODS OF PREPARATION OF MUCOADHESIVE MICROSPHERES

### Ionotropic gelation method

The process of gelation ionotropic produces ice microscopes by interacting polymers between ions, such as alginate or chitosan, and reaction reactions, such as calcium chloride or zinc sulphate. Polymers solutions with drug ingredients begin to dissolve in water baths. The drops of the solution are part of the reaction solution and the reactions that trigger the control, creating the formation of microscopes. The microsheres undergo adequate water washing after forming to remove the remaining unused components. Production techniques benefit from the failure to use chemical organic solvents, as the activity can take place without dangerous components, during environmental security conservation. The nature of Chitosan is especially convenient because the material decreases over time and is suitable for encapsulating proteins and peptides. The main limitation of this method is that the low mechanical quality of the microscopes is created, affecting their structural stability. This technique produces microscopes with limited ability to combine drugs, which affects their effectiveness in administrative applications. [66]




**Figure 6 :- Ionotropic Gelation Method**

### Solvent Evaporation

The Solvent Evaporation Method represents one of the primary methods for preparing microspheres by creating a polymer solution emulsion within an immiscible liquid before eliminating this solution to turn the microspheres into solids. The solution enters an aqueous phase with a polyvinyl alcohol stabilizer to create a lasting emulsion of phases. The microsphere solidification process occurs when the organic solvent evaporates under continuous mixing. The drug stability depends on thorough purification and drying after manufacturing, because organic solvents present toxicity risks and can remain in the final product.[67]

**Coacervation:** A suitable solvent is used to dissolve both drug molecules and polymers before phase separation formation. When a non-solvent enters the solution, it creates phase separation that results in polymer precipitation forming spherical shapes. The microspheres require meticulous washing after formation to eliminate remaining solvents along with impurities, followed by drying. [68]




**Figure 7:- Coacervation**

### Spray Drying Method

The spray drying method serves as the preferred method for creating microspheres according to the magic or suspension of polymer drug solutions or by heating chambers. The drug and polymer mixture is housed in an appropriate solvent before activating the spray process. The heated chamber receives a solution spray from a nozzle that creates a fixed microsphere through rapid evaporation of the solvent. The production

process provides efficient results through rapid execution and scalability parameters, but the drug release mechanism requires microspheres with specific uniform size requirements. [69]

**Emulsification cross-linking method**

The emulsification method combines emulsification steps with chemical networks of mixtures to produce microsphere. The stability of the networking microspheres is accomplished by awarding the strength of the polymer. The main drawback of this process is its use in potentially dangerous networks that represent security risks. A thorough cleaning method requires the microsphere to remove all remaining chemicals, making it suitable for drug testing. [70]

## 9. CHARACTERIZATION OF MUCOADHESIVE MICROSPHERES

**Morphological Characterization**: Morphological characteristics represent an essential process that determines physical appearance, as well as internal surface and micro structure, directly affecting drug release models and drug release, as well as the mechanical properties of the microscope. Scanning electron microscopy (SEM) becomes an essential analytical tool for this study as it reveals high resolution imaging to check the surface properties of microsphere, both smoothness and roughness, and porosity. The smooth surface structure of microsphere is contributing to continuous drug performance, while the porous structure produces better expansion skills to improve responsibility due to the mucosal layer.[71]

**Drug Content:** A precise weight of the prepared drug containing 50 mg microsphere was measured before transferring it to a 100-mL volumetric flask. The preparation received an exact weight measurement of 50 mg microsphere which was dissolved within pH 7.4 phosphate buffer followed by adjustment to volume using the buffer. A method was used to determine the absorbance of the diluted solution after proper solution dilution with correct blank conditions. The drug content measurement of the microsphere depended on a calibration curve. [75]

**Particle Size and Size Distribution:** Directly checks drug availability and release patterns and mucoadhesive output, along with particle properties and their size distribution of mucoadhesives. Microsphere sizes within 10-100 µm show better absorption properties to improve drug absorption of mucosal fabrics, while larger microspheres (100-500 µm) provide local agents that can generate obstacles for absorption due to their dimensions. Optimizing the size of the Microspheres produce better properties of drug retention with controlled release profiles and improved therapeutic outcomes, essentially characterizing microspheres in formulation development. [71]

**Surface Charge (Zeta Potential):** Surface charges on mucoadhesive microspheres determine their stability behaviour and mucosal interaction under zeta potential analysis. When the zeta potential value exceeds ±30 mV it serves as the optimal range because electrostatic repulsion maintains dispersion between microsphere particles. Strong electrostatic interactions form between positive or negatively charged mucoadhesive surfaces and the negatively charged cellular glycoproteins due to high surface electrical charge value.

**Production yield:** The yield from mucoadhesive microsphere production directly indicates both the efficiency of formulation processes and the number of initial materials that transform into final products. Production yield reference the efficiency of formulation by demonstrating minimized material losses while inadequate yields suggest such losses or ineffective processes. [74]

$$\text{Production yield} = \frac{Final\ weight\ of\ microspheres}{TheorTotal\ initial\ weight\ (Polymer+Drug)} \times 100$$

**Swelling index:** The swelling index acts as a fundamental factor that determines mucoadhesive microsphere hydration capacity, thus affecting their adhesive properties and drug delivery characteristics. Microspheres undergo Gravimetric Swelling Studies as the main technique to evaluate this parameter by determining their weight changes before and after exposure to simulated physiological conditions. The optimization of swelling index stands as a critical task because it enables proper alignment between mucoadhesive properties and sustained drug release patterns to obtain effective drug delivery along with extended therapeutic duration.

Swelling index = [(Swollen microsphere size – Dry microsphere size) ÷ Dry microsphere size] × 100

**Determination of Entrapment Efficiency:** The drug concentration quantification within microspheres and drug entrapment efficiency determination through UV-Vis spectroscopy, when linked with high-performance liquid chromatography (HPLC), serves as the analytical method. An increased drug delivery efficiency occurs when drug encapsulation efficiency reaches beyond 80%, yet formulation waste demonstrates the requirement for optimized polymer concentrations or additional cross-linking effects, or enhanced drug-polymer interaction methods. The effectiveness of mucoadhesive microsphere formulation relies on reaching high drug encapsulation efficiency as it delivers maximum therapeutic results and minimizes medication loss. DEE is calculated using the formula: [74]

$$DEE\% = \frac{\text{Entrapped drug}}{\text{Total drug used}} \times 100$$

### *In Vitro* Mucoadhesion Studies of Mucoadhesive Microspheres

*In vitro* mucoadhesion studies assess the ability of mucoadhesive microspheres to adhere to nasal mucosa, enhancing drug retention and absorption. Methods include the falling liquid film test, where microspheres are applied to porcine mucosa and exposed to simulated nasal fluid, and the wash-off test, which measures adhesion after immersion in phosphate buffer saline. Mucoadhesion strength is evaluated using a texture analyzer, recording the detachment force in Newtons. The swelling index determines polymer hydration, impacting adhesion and drug release. Polymers like chitosan, Carbopol, and HPMC exhibit strong mucoadhesion, ensuring prolonged nasal drug delivery for improved therapeutic outcomes. [72]

### *In Vitro* Drug Release Studies of Mucoadhesive Microspheres

*In vitro* drug release studies of mucoadhesive microspheres for nasal delivery, the microspheres are dispersed in phosphate-buffered saline (PBS, pH 6.8, 37°C) using either the dialysis membrane method or direct dispersion method. The release medium is stirred at 50–100 rpm, and samples are collected at set time intervals (0.5–24 hours), replacing the withdrawn volume with fresh PBS to maintain sink conditions. Drug concentration is analyzed using UV-Vis spectrophotometry or HPLC, and release kinetics are evaluated using mathematical models like Zero-order, First-order, Higuchi, or Korsmeyer-Peppas equations. Typically, mucoadhesive microspheres show sustained release with an initial burst effect, aiding in prolonged nasal drug retention and improved bioavailability**.** [73]

**Stability Study:** The ICH guidelines for Accelerated Stability Testing (International Council for Harmonisation) dictate that the microsphere stability should be assessed through exposure to controlled temperature conditions (25°C and 40°C) and humidity levels (60-75% RH) over specified periods to predict their shelf-life duration. The assessment of thermal degradation potential in polymers by monitoring polymer-drug behavior at various temperatures is possible with Differential Scanning Calorimetry (DSC). The analysis using X-ray Diffraction (XRD) probes microsphere crystallinity or amorphous states to confirm that no undesirable storage-related phase transitions will affect drug release kinetics or solubility. Storage analysis via these methods shows that degradation, along with phase separation and mucoadhesive failures, does not occur, thereby ensuring that patients maintain safe drug effectiveness.

## 10. FUTURE PERSPECTIVES

The future of Mucoadhesive microspheres to treat Alzheimer's disease lies in the progression of formula strategies, personalized medical integration, and drug management improvement. Rephrase Researchers should focus on optimizing polymer combinations to improve mucus absorption while minimizing nose irritation, ensuring better compliance of the patient. The combination of biodegradable polymers and biological compatibility, such as PLGA and Pegylated systems, can improve drug stability and dynamic release. In addition, nano formats with surface changes are targeted, such as the combination of the combination, promising to provide accurate drugs with amyloid panels and tau tangles. Accurate and personalized medical approaches will play an important role in optimizing the effectiveness of treatment. With the advancement of the genome and the development of AI-oriented drugs,

therapies can be designed according to genetic signs, such as APOE4, to provide more effective and personalized treatment plans. Automatic learning models can help predict the reaction of the drug and adjust the dose options, ensuring the optimal treatment results for each patient. In addition, combined therapy strategies should be discovered, and target some ways of Alzheimer's disease. The integration of microspheres with single-line antibodies, gene therapies, and RNA interventions can significantly improve disease-modifying treatments. The process of nasal medicine management will also be essential to improve the effectiveness of treatment. The development of intelligent distribution systems with control mechanisms with control, biological sensitivity, and micro-technology can ensure accurate and maintenance of drug management. AI -oriented drug management systems are capable of monitoring nasal absorption, and automatic dose adjustment can further improve patient adherence and treatment effect. For these innovations to achieve a clinical application, in clinical trials in a state is necessary to assess their safety, efficiency, and long-term biological use. The regulatory frame must adapt to adapting to intracranial therapies, ensuring safety standards while facilitating faster approval processes. The cooperation between pharmaceutical industries, university researchers, and regulatory agencies will be very important to fill the gap between research and marketability of the market. By giving current challenges and by taking advantage of emerging technologies, nasal mucous mucus can revolutionize the treatment of Alzheimer's disease, providing an invasive replacement, targeting, and more effective for patients around the world.

## 11. CONCLUSION

The magazine highlights the potential of nasal mucus as a promising drug management system for Alzheimer's (AD). Common treatments for ghosts, such as cholinergic inhibitors and NMDA receptor antagonists, only provide symptoms and limited targeting in the basic pathology of the disease. Brain blood barriers (BBB) limit the penetration of drugs, making oral therapies less efficient. The use of nasal medications seems to be an innovative approach by ignoring the BBB through the ways of the nerves of smell, ensuring the transportation of the drug directly to the brain. Mucoadhesive Microspheres improve the bioavailability of the drug more by prolonging the ability to maintain the drug in the nasal cavity and facilitating the release of controlled drugs. The assessment refers to different materials, such as Chitosan polymers, alginate and synthesis, effective mucus, and maintenance drug use. The process of building microscopes, including nanoparticles, polymer-based systems, and target management strategies, significantly improved the stability, penetration, and effectiveness of the drug. However, some challenges remain, including compliance with patients with potential mucous membranes, unrelated nose absorption due to anatomical transformation, and formula stability problems. Despite these challenges, the management systems of intracranial drugs, especially Mucoadhesive microscopes, have great potential to revolutionize the treatment of ghosts by providing a platform for the use of non-invasive, effective, and targeted drugs.

## 12. REFERENCE


1. B. Wilson, K.M. Geetha, Neurotherapeutic applications of nanomedicine for treating Alzheimer’s disease, J. Control. Release 325 (2020) 25–37.
2. Health, A.I.o.; Welfare, Dementia in Australia, AIHW, Canberra, 2023.
3. A.S.A. Dementia, Alzheimer’s disease facts and figures; 1552-5260 2023, Wiley, 2023, pp. 1598–1695.
4. W.J. Deardorff, G. Grossberg, A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease, Drug Des. Dev. Ther. 10 (2016) 3267–3279, https://doi.org/10.2147/dddt. s86463
5. Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024). Alzheimer’s disease current therapies, novel drug delivery systems and future directions for better disease management. In *Journal of Controlled Release* (Vol. 367, pp. 402–424). Elsevier B.V. https://doi.org/10.1016/j.jconrel.2024.01.047
6. Y.H. Kim, D.W. Lee, E.J. Jung, J.T. Bae, S.G. Lee, H.B. Pyo, K.H. Kang, D.K. Lee, Preparation and characterization of quercetin-loaded silica microspheres stabilized by combined multiple emulsion and sol-gel processes, Chem. Ind. Chem. Eng. Q. 21 (1–1) (2015) 85–94.
7. A.R. Khan, X. Yang, M. Fu, G. Zhai, Recent progress of drug nanoformulations targeting to brain, J. Control. Release 291 (2018) 37–64.
8. V. Agrahari, P.-A. Burnouf, T. Burnouf, V. Agrahari, Nanoformulation properties, characterization, and behavior in complex biological matrices: challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential, Adv. Drug Deliv. Rev. 148 (2019) 146–180.
9. Pasteur, M., Arsouze, G., Ilango, G., le Pennec, D., Kulker, D., Heyraud, A., Cottier, J. P., Aussedat, C., Heuzé-Vourc’h, N., Hervé, V., & le Guellec, S. (2024).

Characterization of anatomical variations of the nasal cavity in a subset of European patients and their impact on intranasal drug delivery. *International Journal of Pharmaceutics*, *667*. https://doi.org/10.1016/j.ijpharm.2024.124851

10. Sun, Q., Zhang, Y., Tian, L., Tu, J., Corley, R., Kuprat, A. P., & Dong, J. (2024). Investigation of inter-subject variation in ultrafine particle deposition across human nasal airways: A study involving children, adults, and the elderly. *Science of the Total Environment*, *955*. https://doi.org/10.1016/j.scitotenv.2024.177028
11. Hiti, Sanshita, & Singh, I. (2023). Nasal implants for drug delivery: Advancements and applications. In *Chinese Journal of Plastic and Reconstructive Surgery* (Vol. 5, Issue 4, pp. 217–220). KeAi Communications Co. https://doi.org/10.1016/j.cjprs.2023.09.004
12. Talebi, M., Shahbazi, K., Dakkali, M. S., Akbari, M., Almasi Ghale, R., Hashemi, S., Sashourpour, M., Mojab, F., & Aminzadeh, S. (2025). Phytosomes: A promising nanocarrier system for enhanced bioavailability and therapeutic efficacy of herbal products. *Phytomedicine Plus*, *5*(2), 100779. https://doi.org/10.1016/j.phyplu.2025.100779
13. Sadiq, A. H., Alam, M. J., Begum, F., Hasan, M., Kristof, J., Mamun, M. al, Maniruzzaman, M., Shimizu, K., Kanazawa, T., Kahyo, T., Setou, M., & Shimizu, K. (2025). Enhancing Galantamine Distribution in Rat Brain Using Microplasma-Assisted Nose-to-Brain Drug Delivery. *International Journal of Molecular Sciences*, *26*(4). https://doi.org/10.3390/ijms26041710
14. Sidhaye, I., Karadagi, A., Harish, H. K. H., Meti, V., Dasankoppa, F. S., & Swamy, A. H. V. (2025). Recent Advances in Intranasal Delivery with Lipid Nanoparticles for Brain Targeting: A Review. *Journal of Young Pharmacists*, *17*(1), 54–61. https://doi.org/10.5530/jyp.20251166
15. Romeo, V., Jacob, A., & Agrawal, M. (2020). Bioavailability challenges in nasal drug delivery and strategies to overcome them. *Current Drug Delivery, 17(9), 785–798*
16. Kothamasu, S., Hyma, M., & Thangabalan, B. (2024). A REVIEW ON NASO PULMONARY DRUG DELIVERY SYSTEM. *Certified Journal | Kothamasu et al. World Journal of Pharmaceutical Research*, *13*. https://doi.org/10.20959/wjpr202424-34961
17. Mubarak, N., Waqar, M. A., Khan, A. M., Asif, Z., Alvi, A. S., Virk, A. A., & Amir, S. (2025). A comprehensive insight of innovations and recent advancements in nanocarriers for nose-to-brain drug targeting. In *Designed Monomers and Polymers* (Vol. 28, Issue 1, pp. 7–29). Taylor and Francis Ltd. https://doi.org/10.1080/15685551.2025.2464132
18. Meredith, S. J., Doods, H., Smith, D. J., & Kozlowski, E. A. (2020). **Nasal drug delivery: Challenges, advances, and future directions.** *Journal of Pharmaceutical Sciences, 109(8), 2431–2450.*
19. Madadi, A. K., & Sohn, M. J. (2024). Advances in Intrathecal Nanoparticle Delivery: Targeting the Blood–Cerebrospinal Fluid Barrier for Enhanced CNS Drug Delivery. In *Pharmaceuticals* (Vol. 17, Issue 8). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/ph17081070
20. Hayden, M. R., & Tyagi, N. (2024). Sodium Thiosulfate: An Innovative Multi-Target Repurposed Treatment Strategy for Late-Onset Alzheimer's Disease. In *Pharmaceuticals* (Vol. 17, Issue 12). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/ph17121741
21. Dighe, S., Jog, S., Momin, M., Sawarkar, S., & Omri, A. (2023). Intranasal drug delivery by nanotechnology: Advances and challenges for Alzheimer's disease management. *Pharmaceutics, 16*(1), 58. MDPI.
22. Cimino, C., Bonaccorso, A., Tomasello, B., Alberghina, G. A., Musumeci, T., Puglia, C., Pignatello, R., Marrazzo, A., & Carbone, C. (2024). W/O/W Microemulsions for Nasal Delivery of Hydrophilic Compounds: A Preliminary Study. *Journal of Pharmaceutical Sciences*, *113*(6), 1636–1644. https://doi.org/10.1016/j.xphs.2024.01.013
23. Luo, D., Ni, X., Yang, H., Feng, L., Chen, Z., & Bai, L. (2024). A comprehensive review of advanced nasal delivery: Specially insulin and calcitonin. In *European Journal of Pharmaceutical Sciences* (Vol. 192). Elsevier B.V. https://doi.org/10.1016/j.ejps.2023.106630
24. Zaidi, S. (2024). OPTIMIZATION AND CHARACTERIZATION OF MICROSPHERE FORMULATIONS FOR CONTROLLED DRUG DELIVERY OF CARVEDILOL. *Article in African Journal of Biological Sciences*. https://doi.org/10.33472/AFJBS.6.6.2024.8356-8372
25. Babu, G. N., Muthukaruppan, M., & Ahad, H. A. (2025). Azadirachta indica Fruit Mucilage Aided Mucoadhesive Microspheres of Acyclovir for Drug Entrapment and Mucoadhesive Time Assets with Design-Expert Software. *Indian Journal of Pharmaceutical Education and Research*, *59*(1), s243–s255. https://doi.org/10.5530/ijper.20256428
26. Vyas, S., Anitha, K. N., Mudduluru, N. B., & Devhare, L. D. (2024). Quality by Design Approach to Nasal Mucoadhesive Microspheres: Enhanced Sumatriptan Succinate Delivery through Formulation and Characterization. *International Journal of Drug Delivery Technology*, *14*(3), 1644–1651. https://doi.org/10.25258/ijddt.14.3.56
27. Paria, A. (2025). *Assessment of Berberine-Loaded Mucoadhesive Microspheres for Targeted Peptic Ulcer Therapy Article in South Eastern European Journal of Public Health*. https://www.researchgate.net/publication/388124925
28. Subhash Pangarekar, S., Deshmukh, T. V., Narwade, C. G., Pune, M. B. B., & Maharashtra, I. (2025). CURRENT TRENDS AND ADVANCES IN MUCOADHESIVE MICROSPHERES: A NOVEL APPROACH OF CONTROLLED RELEASE DRUG DELIVERY *Corresponding Author. *Certified Journal | 418 World Journal of Pharmaceutical Research SJIF Impact Factor 8*, *14*, 419. https://doi.org/10.20959/wjpr20254-35588
29. B. S., S. M., T. S., & S. S. (2024). A Research Work on Design, Development and In-Vitro Evaluation of Losartan Potassium Loaded Pectinate Microspheres. *International Journal For Multidisciplinary Research*, *6*(2). https://doi.org/10.36948/ijfmr.2024.v06i02.15156

30. Patel, D. M., Patel, D. J., Shah, S. K., & Shah, A. S. (2020). FORMULATION AND evaluation of fast dissolving tablets of nebivolol and valsartan. *International Journal of Pharmaceutical Sciences and Research*, *11*(11), 5530. https://doi.org/10.13040/IJPSR.0975-8232.11(11).5530-39
31. Dave Singh, G., Nam Kim, H., Hwan Kim, S., & Wang, L. (2021). 3D craniofacial and upper airway changes after biomimetic oral appliance therapy in Korean adults. *Otorhinolaryngology-Head and Neck Surgery*, *6*(2). https://doi.org/10.15761/ohns.1000263
32. Sharma, A. K., Goyal, V., & Sankhla, S. (2022). Knowledge, attitude and practice towards antibiotic use and antibiotic resistance among medical students: a cross-sectional study. *International Journal of Pharmaceutical Sciences and Research*, *13*(10), 4166. https://doi.org/10.13040/IJPSR.0975-8232.13(10).4166-72
33. Garg, Vikas & Srivastav, Shalini & Gupta, Anubhuti. (2018). Application of Artificial Intelligence for Sustaining Green Human Resource Management. 113-116. 10.1109/ICACE.2018.8686988.
34. Su, J., Liu, Y., Sun, H., Naeem, A., Xu, H., Qu, Y., Wang, C., Li, Z., Lu, J., Wang, L., Wang, X., Wu, J., Sun, L., Zhang, J., Wang, Z., Yang, R., & Wu, L. (2024). Visualization of nasal powder distribution using biomimetic human nasal cavity model. *Acta Pharmaceutica Sinica B*, *14*(1), 392–404. https://doi.org/10.1016/j.apsb.2023.06.007
35. Bishan Sarkar, Sourav Mandal, & Suchetan Sarkar. (2024). A Research Work on Design, Development and In-Vitro Evaluation of Losartan Potassium Loaded Pectinate Microspheres. *International Journal For Multidisciplinary Research*, *6*(2). https://doi.org/10.36948/ijfmr.2024.v06i02.15156
36. Subhash Pangarekar, S., Deshmukh, T. V., Narwade, C. G., Pune, M. B. B., & Maharashtra, I. (2025). Current trends and advances in mucoadhesive microspheres: a novel approach of controlled release drug delivery *Corresponding Author. *Certified Journal* | *418 World Journal of Pharmaceutical Research SJIF Impact Factor 8*, *14*, 419. https://doi.org/10.20959/wjpr20254-35588
37. Boyuklieva, R., Katsarov, P., Zagorchev, P., Abarova, S., Hristozova, A., & Pilicheva, B. (2024). Idebenone-Loaded Nanocomposite Microspheres for Nasal Administration—A Perspective in the Treatment of Alzheimer's Disease. *Discovery Medicine*, *36*(187), 1572. https://doi.org/10.24976/discov.med.202436187.144
38. Akram, W., Singh, N., Sahu, K. K., & Garud, N. (2025). Designing & optimisation of dual $Ca^{2+}$ and $SO_4^{2-}$ ionic cross-linked sericin/pectin microbeads using response surface methodology for colon-specific delivery. *Journal of Biomaterials Science, Polymer Edition*, 1–26.https://doi.org/10.1080/09205063.2025.2450930
39. Huang, Y., Xu, W., & Zhou, R. (2021). NLRP3 inflammasome activation and cell death. In *Cellular and Molecular Immunology* (Vol. 18, Issue 9, pp. 2114–2127). Springer Nature. https://doi.org/10.1038/s41423-021-00740-6
40. de Sousa Fernandes, M. S., Ordônio, T. F., Santos, G. C. J., Santos, L. E. R., Calazans, C. T., Gomes, D. A., & Santos, T. M. (2020). Effects of Physical Exercise on Neuroplasticity and Brain Function: A Systematic Review in Human and Animal Studies. In *Neural Plasticity* (Vol. 2020). Hindawi Limited. https://doi.org/10.1155/2020/8856621
41. Kiedrowski MR, Horswill AR. New approaches for treating staphylococcal biofilm infections. Ann N Y Acad Sci. 2011 Dec;1241:104-21. doi: 10.1111/j.1749-6632.2011.06281.x. PMID: 22191529.
42. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007 Jun 7;337(1-2):1-24. doi: 10.1016/j.ijpharm.2007.03.025. Epub 2007 Mar 25. PMID: 17475423.
43. Tomarchio, E. G., Zagni, C., Dattilo, S., Vitiello, L., Fuochi, V., Furnari, S., Furneri, P. M., Granata, G., Carroccio, S. C., & Rescifina, A. (2025). Advanced cyclodextrin-based multiloaded hydrogels for targeted drug delivery in the fight against vaginal fungal infections. *Carbohydrate Polymers*, *356*. https://doi.org/10.1016/j.carbpol.2025.123412
44. Jahanbekam, S., Asare-Addo, K., Alipour, S., & Nokhodchi, A. (2025). Smart hydrogels and the promise of multi-responsive in-situ systems. In *Journal of Drug Delivery Science and Technology* (Vol. 107). Editions de Sante. https://doi.org/10.1016/j.jddst.2025.106758
45. Daré, R. G., & Lautenschlager, S. O. S. (2025). Nanoparticles with Antioxidant Activity. In *Antioxidants* (Vol. 14, Issue 2). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/antiox14020221
46. Mulumba, J., Duan, R., Luo, B., Wu, J., Sulaiman, M., Wang, F., & Yang, Y. (2025). The role of neuroimaging in Alzheimer's disease: implications for the diagnosis, monitoring disease progression, and treatment. *Exploration of Neuroscience*, *4*. https://doi.org/10.37349/en.2025.100675
47. Goyal, A., Kumari, A., Verma, A., Chaudhary, V., Pathak, P., & Yadav, H. N. (2025). Nature's neuroprotector: Honokiol and its promise for Alzheimer's and Parkinson's. *Brain Disorders*, *17*, 100208. https://doi.org/10.1016/j.dscb.2025.100208
48. Mulumba, J., Duan, R., Luo, B., Wu, J., Sulaiman, M., Wang, F., & Yang, Y. (2025). The role of neuroimaging in Alzheimer's disease: implications for the diagnosis, monitoring disease progression, and treatment. *Exploration of Neuroscience*, *4*. https://doi.org/10.37349/en.2025.100675
49. Rahman, A., Banu, Z., Rani, R., & Mehdiya, R. (2024). Unravelling Alzheimer's disease: Insights into pathophysiology, etiology, diagnostic approaches, and the promise of aducanumab, lecanemab, and donanemab. *Journal of Phytonanotechnology and Pharmaceutical Sciences*, *4*(3). https://doi.org/10.54085/jpps.2024.4.3.1
50. Zheng, J.-Y., Lu, H., Liu, W.-T., Sun, J., Lei, Z.-M., Zeng, C.-Y., Zhu, C.-D., Xiang, Y., Tan, G.-Y., Peng, Q.-K., & Sun, Y.-R. (2025). NRF2 signalling: an

emerging therapeutic target for Alzheimer's disease. *Pharmacology Discovery*, *5*(1), 1. https://doi.org/10.53388/PD202505001

51. Lin, T. K., Huang, C. R., Lin, K. J., Hsieh, Y. H., Chen, S. der, Lin, Y. C., Chao, A. C., & Yang, D. I. (2024). Potential Roles of Hypoxia-Inducible Factor-1 in Alzheimer's Disease: Beneficial or Detrimental? In *Antioxidants* (Vol. 13, Issue 11). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/antiox13111378
52. Lietzau, G. (2024). Neurobiology Research on Neurodegenerative Disorders. In *Brain Sciences* (Vol. 14, Issue 11). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/brainsci14111121
53. Al-Thani, N. A., Zinck, D., Stewart, G. S., & Costello, D. A. (2024). Modulation of Urea Transport Attenuates TLR2-Mediated Microglial Activation and Upregulates Microglial Metabolism In Vitro. *Metabolites*, *14*(11). https://doi.org/10.3390/metabo14110634
54. Șovrea, A. S., Boșca, A. B., Dronca, E., Constantin, A. M., Crintea, A., Suflețel, R., Ștefan, R. A., Ștefan, P. A., Onofrei, M. M., Tschall, C., & Crivii, C. B. (2025). Non-Drug and Non-Invasive Therapeutic Options in Alzheimer's Disease. In *Biomedicines* (Vol. 13, Issue 1). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/biomedicines13010084
55. CHENCHULA, S., Anitha, K., Singh, M. K., Posinasetty, B., R, P., & Chikatipalli, R. (2023). *Recent Insights into Neurobiology of Alzheimer's Disease and Advanced Treatment Strategies.* https://doi.org/10.22541/au.170065118.81840410/v1
56. Athar, T., al Balushi, K., & Khan, S. A. (2021). Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease. In *Molecular Biology Reports* (Vol. 48, Issue 7, pp. 5629–5645). Springer Science and Business Media B.V. https://doi.org/10.1007/s11033-021-06512-9
57. Arya, R., Jain, S., Paliwal, S., Madan, K., Sharma, S., Mishra, A., Tiwari, P., & Kadiri, S. K. (2024). BACE1 inhibitors: A promising therapeutic approach for the management of Alzheimer's disease. In *Asian Pacific Journal of Tropical Biomedicine* (Vol. 14, Issue 9, pp. 369–381). Wolters Kluwer Medknow Publications. https://doi.org/10.4103/apjtb.apjtb_192_24
58. Wong, C. Y. J., Baldelli, A., Tietz, O., van der Hoven, J., Suman, J., Ong, H. X., & Traini, D. (2024). An overview of in vitro and in vivo techniques for characterization of intranasal protein and peptide formulations for brain targeting. In *International Journal of Pharmaceutics* (Vol. 654). Elsevier B.V. https://doi.org/10.1016/j.ijpharm.2024.123922
59. Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024). Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management. In *Journal of Controlled Release* (Vol. 367, pp. 402–424). Elsevier B.V. https://doi.org/10.1016/j.jconrel.2024.01.047
60. Amaral, D. G., Augustinack, J., Barbas, H., Frosch, M., Gabrieli, J., Luebke, J., Rakic, P., Rosene, D., & Rushmore, R. J. (2024). The analysis of H.M.'s brain: A brief review of status and plans for future studies and tissue archive. In *Hippocampus* (Vol. 34, Issue 2, pp. 52–57). John Wiley and Sons Inc. https://doi.org/10.1002/hipo.23597
61. Lazarov, O., & Hollands, C. (2016). Hippocampal neurogenesis: Learning to remember. In *Progress in Neurobiology* (Vols. 138–140, pp. 1–18). Elsevier Ltd. https://doi.org/10.1016/j.pneurobio.2015.12.006
62. Șovrea, A. S., Boșca, A. B., Dronca, E., Constantin, A. M., Crintea, A., Suflețel, R., Ștefan, R. A., Ștefan, P. A., Onofrei, M. M., Tschall, C., & Crivii, C. B. (2025). Non-Drug and Non-Invasive Therapeutic Options in Alzheimer's Disease. In *Biomedicines* (Vol. 13, Issue 1). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/biomedicines13010084
63. Athar, T., al Balushi, K., & Khan, S. A. (2021). Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease. In *Molecular Biology Reports* (Vol. 48, Issue 7, pp. 5629–5645). Springer Science and Business Media B.V. https://doi.org/10.1007/s11033-021-06512-9
64. CHENCHULA, S., Anitha, K., Singh, M. K., Posinasetty, B., R, P., & Chikatipalli, R. (2023). *Recent Insights into Neurobiology of Alzheimer's Disease and Advanced Treatment Strategies.* https://doi.org/10.22541/au.170065118.81840410/v1
65. Arya, R., Jain, S., Paliwal, S., Madan, K., Sharma, S., Mishra, A., Tiwari, P., & Kadiri, S. K. (2024). BACE1 inhibitors: A promising therapeutic approach for the management of Alzheimer's disease. In *Asian Pacific Journal of Tropical Biomedicine* (Vol. 14, Issue 9, pp. 369–381). Wolters Kluwer Medknow Publications. https://doi.org/10.4103/apjtb.apjtb_192_24
66. Varalaxmi, S., Reddy, A. V. D. K., Sai, B. A., Reshika, B., Bhargavi, B., Raja, B. R., & Harshitha, S. (2024). Development and Characterization of Ranitidine Hydrochloride Mucoadhesive Hydrogel Beads. *Indian Journal Of Science And Technology*, *17*(44), 4669–4678. https://doi.org/10.17485/IJST/v17i44.3027
67. Verma, S., & Kumari, N. (2022). Study an effect of various orgainic solvents for preparation of glipizide mucoadhesive microspheres. *International Journal of Health Sciences*, 11054–11067. https://doi.org/10.53730/ijhs.v6ns5.10966
68. Khan, M., Ansari, V., Kushwaha, P., Kumar, A., Ansari, V. A., & Akhtar, J. (2015). Mucoadhesive microspheres for controlled delivery of drugs. *Article in Asian Journal of Pharmaceutical and Clinical Research*, *8*. https://www.researchgate.net/publication/325334544
69. Soni, G. (2021). Preparation and Characterization of Microspheres for the Anticancer Activity. *International Journal for Research in Applied Science and Engineering Technology*, *9*(5), 574–587. https://doi.org/10.22214/ijraset.2021.34263
70. Dhembre, G., Jaiswal, S. B., Jadhao, U. T., Ali, A., Dhembre, G. N., Wathore, S. A., & Thoke, S. T. (2024). European Journal of Biomedical and Pharmaceutical Sciences formulation and evaluation of carvedilol nasal microspheres. In *www.ejbps.com* | (Vol. 11). https://www.researchgate.net/publication/384640582
71. Shankar Gupta, P. (2024). Fabrication and evaluation of mucoadhesive gastroretentive microspheres of

oxcarbazepine. *Article in African Journal of Biological Sciences*. https://doi.org/10.33472/AFJBS.6.10.2024.4895-4912

72. Gunes, M., Turan, G., Kose, F. A., Ozer, Ö., & Karavana, S. Y. (2024). Rasagiline mesylate mucoadhesive buccal microsphere-loaded gel formulations: A new candidate for non-oral Parkinson's treatment. *Acta Pharmaceutica Sciencia*, *62*(4), 887–906. https://doi.org/10.23893/1307-2080.APS6258
73. Sarkar, A., & Mandal, S. (2025). Sodium Alginate in Mucoadhesive Drug Delivery Systems: A Comprehensive Review of Properties, Dosage Forms, And Characterization Methods 906-928 | Article in. *International Journal of Pharmaceutical Sciences*. https://doi.org/10.5281/zenodo.14636331
74. Zaidi, S. (2024). Optimization and characterization of microsphere formulations for controlled drug delivery of carvedilol. *Article in African Journal of Biological Sciences*. https://doi.org/10.33472/AFJBS.6.6.2024.8356-8372
75. Komati, S., Swain, S., Rao, M. E. B., Jena, B. R., Unnam, S., & Dasi, V. (2018). QbD-based design and characterization of mucoadhesive microspheres of quetiapine fumarate with improved oral bioavailability and brain biodistribution potential. *Bulletin of Faculty of Pharmacy, Cairo University*, *56*(2), 129–145.